EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Cytosolic DNA sensor AIM2 promotes KRAS ‐driven lung cancer independent of inflammasomes

Mohammad Alanazi, Teresa Weng, Louise McLeod, Linden J Gearing, Julian A Smith, Beena Kumar, Mohamed I Saad iD, Brendan J Jenkins iD

Cancer Science · 2024

DOI: 10.1111/cas.16171 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Science, 2024. Verfasst von Mohammad Alanazi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia. Hauptthemen laut MEDLINE: Inflammasomes, Lung Neoplasms, Proto-Oncogene Proteins p21(ras), DNA-Binding Proteins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Constitutively active KRAS mutations are among the major drivers of lung cancer, yet the identity of molecular co‐operators of oncogenic KRAS in the lung remains ill‐defined. The innate immune cytosolic DNA sensor and pattern recognition receptor (PRR) Absent‐in‐melanoma 2 (AIM2) is best known for its assembly of multiprotein inflammasome complexes and promoting an inflammatory response. Here, we define a role for AIM2, independent of inflammasomes, in KRAS‐addicted lung adenocarcinoma (LAC). In genetically defined and experimentally induced (nicotine‐derived nitrosamine ketone; NNK) LAC mouse models harboring the Kras G12D driver mutation, AIM2 was highly upregulated compared with other cytosolic DNA sensors and inflammasome‐associated PRRs. Genetic ablation of AIM2 in Kras G12D and NNK‐induced LAC mouse models significantly reduced tumor growth, coincident with reduced cellular proliferation in the lung. Bone marrow chimeras suggest a requirement for AIM2 in Kras G12D ‐driven LAC in both hematopoietic (immune) and non‐hematopoietic (epithelial) cellular compartments, which is supported by upregulated AIM2 expression in immune and epithelial cells of mutant KRAS lung tissues. Notably, protection against LAC in AIM2‐deficient mice is associated with unaltered protein levels of mature Caspase‐1 and IL‐1β inflammasome effectors. Moreover, genetic ablation of the key inflammasome adapter, ASC, did not suppress Kras G12D ‐driven LAC. In support of these in vivo findings, AIM2, but not mature Caspase‐1, was upregulated in human LAC patient tumor biopsies. Collectively, our findings reveal that endogenous AIM2 plays a tumor‐promoting role, independent of inflammasomes, in mutant KRAS‐addicted LAC, and suggest innate immune DNA sensing may provide an avenue to explore new therapeutic strategies in lung cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

InflammasomesLung NeoplasmsProto-Oncogene Proteins p21(ras)DNA-Binding ProteinsAdenocarcinoma of LungAnimalsMiceHumansCaspase 1Interleukin-1betaMutationNitrosaminesFemaleCytosolCell ProliferationCell Line, Tumor

Stichwörter der Autor:innen

cell proliferationinflammasomeinnate immunitylung cancerpattern recognition receptors

Substanzen

InflammasomesProto-Oncogene Proteins p21(ras)DNA-Binding ProteinsAim2 protein, mouseAIM2 protein, humanCaspase 1Hras protein, mouseKRAS protein, humanInterleukin-1betaNitrosamines

Autor:innen und Institutionen

  • Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Victoria, Australia.
  • Department of Molecular and Translational Sciences, Monash University, Clayton, Victoria, Australia.
  • Department of Surgery, School of Clinical Sciences/Monash Health, Monash University, Clayton, Victoria, Australia.
  • Department of Anatomical Pathology, Monash Health, Clayton, Victoria, Australia.
  • South Australian immunoGENomics Cancer Institute (SAiGENCI), The University of Adelaide, Adelaide, South Australia, Australia.

ORCID-Profile: Mohamed I Saad, Brendan J Jenkins

Zitieren

APA

Alanazi, M., Weng, T., McLeod, L., Gearing, L. J., Smith, J. A., Kumar, B., Saad, M. I., & Jenkins, B. J. (2024). Cytosolic DNA sensor AIM2 promotes KRAS ‐driven lung cancer independent of inflammasomes. Cancer Science. https://doi.org/10.1111/cas.16171

Vancouver

Alanazi M, Weng T, McLeod L, Gearing LJ, Smith JA, Kumar B, et al. Cytosolic DNA sensor AIM2 promotes KRAS ‐driven lung cancer independent of inflammasomes. Cancer Science. 2024. doi:10.1111/cas.16171

BibTeX
@article{Alanazi2024,
  author = {Alanazi, Mohammad and Weng, Teresa and McLeod, Louise and Gearing, Linden J and Smith, Julian A and Kumar, Beena and Saad, Mohamed I and Jenkins, Brendan J},
  title = {Cytosolic DNA sensor AIM2 promotes KRAS ‐driven lung cancer independent of inflammasomes},
  journal = {Cancer Science},
  year = {2024},
  doi = {10.1111/cas.16171}
}
Kostenlos starten →